Cystatin B Attenuates Cerebral Ischemia Reperfusion Injury by Inhibiting the JAK2 / STAT3 Signaling Pathway
CNS Neuroscience & Therapeutics · 2026-04 · 32 (4)
DOI: 10.1002/cns.70818 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 29.03.2026. Verfasst von Gang Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Huanggang Central Hospital of Yangtze University, Huanggang, China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Janus Kinase 2, Signal Transduction, Reperfusion Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Cerebral ischemia reperfusion injury (CIRI) poses a significant clinical and economic burden worldwide. Therefore, it is essential to identify key regulators that may improve stroke prognosis. Cystatin B (CSTB) is known to be involved in neuroprotection, inflammation modulation, and apoptosis regulation, but its specific function and mechanisms in CIRI remain unclear.
Methods
We employed gain‐ and loss‐of‐function approaches in a mouse model of transient middle cerebral artery occlusion (t/MCAO) and in cultured neurons subjected to oxygen–glucose deprivation/reperfusion (OGD/R). The effects were evaluated primarily using a combination of quantitative PCR, Western blot, and immunofluorescence staining to assess neurological deficits, inflammatory responses, and apoptosis, as well as to elucidate the underlying mechanisms.
Results
Our findings demonstrated that CSTB significantly attenuated CIRI, as evidenced by the mitigation of neurological deficits, inflammation, and apoptosis. Mechanistically, the protective effects of CSTB were associated with the suppression of the JAK2/STAT3 signaling pathway.
Conclusion
This study identifies CSTB as a novel negative regulator of CIRI. Its protective role is mediated through the inhibition of apoptosis and inflammatory responses via the JAK2/STAT3 axis, suggesting its potential as a therapeutic target for ischemic stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Huanggang Central Hospital of Yangtze University, Huanggang, China.
- Medical Science Research Center, Zhongnan Hospital; Basic Medical School, Wuhan University, Wuhan, China.
- Basic Medical School, Wuhan University, Wuhan, China.
ORCID-Profile: Fengjiao Hu, Jinhua Wang
Förderung
- Hubei Provincial Natural Science Foundation of China
Zitieren
APA
Zhou, G., Hu, F., Gao, J., Wang, L., Wu, X., Tian, Y., Zhang, P., Xia, G., Wan, F., & Wang, J. (2026). Cystatin B Attenuates Cerebral Ischemia Reperfusion Injury by Inhibiting the JAK2 / STAT3 Signaling Pathway. CNS Neuroscience & Therapeutics, 32(4). https://doi.org/10.1002/cns.70818
Vancouver
Zhou G, Hu F, Gao J, Wang L, Wu X, Tian Y, et al. Cystatin B Attenuates Cerebral Ischemia Reperfusion Injury by Inhibiting the JAK2 / STAT3 Signaling Pathway. CNS Neuroscience & Therapeutics. 2026;32(4). doi:10.1002/cns.70818
BibTeX
@article{Zhou2026,
author = {Zhou, Gang and Hu, Fengjiao and Gao, Ju and Wang, Lei and Wu, Xiangbo and Tian, Yu and Zhang, Peng and Xia, Guangming and Wan, Feng and Wang, Jinhua},
title = {Cystatin B Attenuates Cerebral Ischemia Reperfusion Injury by Inhibiting the JAK2 / STAT3 Signaling Pathway},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {4},
doi = {10.1002/cns.70818}
}
EUVIMED